MD1003, a high-dose biotin developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced at the Oct. 25–28 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France.
The effects of the treatment were seen to be upheld over time and benefitted all patients in the trial similarly, offering hope to progressive MS patients that a new treatment for their condition may be on the horizon.
Presented by a team of researchers in France, the poster titled, “Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-up data,” highlighted robust effects of high-dose biotin over several years.
The MS-SPI Phase 3 trial (NCT02220933) included patients with progressive MS with no inflammatory disease activity. Patients were randomly assigned to treatment with 100 mg of MD1003 three times daily, or a placebo.
In total, 103 patients received MD1003 and 51 were on placebo treatment. Participants in the placebo group (42 patients) were switched to MD1003 after 12 months.
After nine months, 13% of MD1003-treated patients had improved their Expanded Disability Status Scale (EDSS) scores and performed better on the timed 25-foot walk, a measure of mobility and leg function. Meanwhile, none of the patients receiving a placebo had improved. This proportion remained stable over the next two years.
Researchers noted that while the change in EDSS was halted among placebo-treated patients when they switched to MD1003, they remained at a higher level throughout the study, suggesting that earlier treatment is advisable.
At 36 months, 67% of those who received MD1003 throughout the study had experienced an adverse event, compared to 79% of those who first received a placebo.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?